BiologicalDrug
Alglucosidase alfa clinical trials
Also written Myozyme and Lumizyme®.
- studies test it
- 23
- open now
- 0
- in phase 3
- 4
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
23 studies that test it; most in 2003 (5)
| Year | Studies |
|---|---|
| 2003 | 5 |
| 2004 | 1 |
| 2005 | 4 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 9
- Phase 3
- 4
- Phase 4
- 11
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 0
Often tested with
Tested in the same studies.
Duvoglustat (1) · Avalglucosidase alfa (1)
Studies
Open first, then newest update. How each study uses alglucosidase alfa is read from its arms, and is right about nine times in ten.
Testing it · 23
- A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase AlfaActive, not recruitingPhase 2Genzyme, a Sanofi CompanyNCT03019406Written as Alglucosidase alfa (GZ419829)
- Drug-drug Interaction StudyCompletedPhase 2Amicus TherapeuticsNCT01380743Written as rhGAA
- Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa TreatmenCompletedPhase 4Genzyme, a Sanofi CompanyNCT04676373Written as ALGLUCOSIDASE ALFA
- Growth and Development Study of Alglucosidase AlfaCompletedPhase 4Genzyme, a Sanofi CompanyNCT00486889Written as alglucosidase alfa
- Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa TreatmentCompletedPhase 4Genzyme, a Sanofi CompanyNCT03687333Written as ALGLUCOSIDASE ALFA (MYOZYME)
- Immune Tolerance Induction StudyTerminatedPhase 4Genzyme, a Sanofi CompanyNCT00701701Written as Myozyme® (alglucosidase alfa)
- Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe DiseaseCompletedPhase 4Genzyme, a Sanofi CompanyNCT01410890Written as alglucosidase alfa
- A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe DiseaseTerminatedPhase 4Genzyme, a Sanofi CompanyNCT01597596Written as alglucosidase alfa
- A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe DiseaseTerminatedPhase 4Genzyme, a Sanofi CompanyNCT01526785Written as Alglucosidase alfa
- A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe DiseaseCompletedPhase 3Genzyme, a Sanofi CompanyNCT00158600Written as alglucosidase alfa
- Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase AlfaCompletedPhase 4Genzyme, a Sanofi CompanyNCT01288027Written as Alglucosidase Alfa
- An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe DiseaseCompletedPhase 4Genzyme, a Sanofi CompanyNCT00701129Written as Alglucosidase Alfa
- Late-Onset Treatment Study Extension ProtocolCompletedPhase 4Genzyme, a Sanofi CompanyNCT00455195Written as alglucosidase alfa
- High Dose or High Dose Frequency Study of Alglucosidase AlfaCompletedPhase 4Genzyme, a Sanofi CompanyNCT00483379Written as alglucosidase alfa
- A Study of rhGAA in Patients With Late-Onset Pompe DiseaseCompletedPhase 2Genzyme, a Sanofi CompanyNCT00250939Written as Myozyme
- Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602CompletedPhase 2/3Genzyme, a Sanofi CompanyNCT00125879Written as Myozyme
- Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe DiseaseCompletedNot applicableGenzyme, a Sanofi CompanyNCT00074932Written as Myozyme
- rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)CompletedPhase 1/2Genzyme, a Sanofi CompanyNCT00053573Written as Myozyme
- A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe DiseaseCompletedPhase 2/3Genzyme, a Sanofi CompanyNCT00059280Written as Myozyme
- Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory SupportCompletedPhase 3Genzyme, a Sanofi CompanyNCT00268944Written as Myozyme
See all 23 studies that test alglucosidase alfa →
As the comparator · 3 — what is tested is compared with alglucosidase alfa
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe DiseaseCompletedPhase 3Amicus TherapeuticsNCT03729362Written as Alglucosidase Alfa
- Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe DiseaseCompletedPhase 3Genzyme, a Sanofi CompanyNCT02782741Written as Alglucosidase alfa (GZ419829)
- VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe DiseaseTerminatedPhase 1/2Valerion Therapeutics, LLCNCT02898753Written as RhGAA
Codes
What other systems call alglucosidase alfa · ClinicalTrials.gg INT002185
- MeSH (NLM) C000731976alglucosidase alfaOne source NLM
- UNII (FDA) DTI67O9503ALGLUCOSIDASE ALFAConfirmed FDA, NLM, Wikidata
- RxNorm 629565Confirmed FDA, Wikidata
- Wikidata Q2919537alglucosidase alfaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65221Alglucosidase AlfaOne source FDA
- DrugBank DB01272One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731976 | alglucosidase alfa | One source NLM |
| UNII (FDA) | DTI67O9503 | ALGLUCOSIDASE ALFA | Confirmed FDA, NLM, Wikidata |
| RxNorm | 629565 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2919537 | alglucosidase alfa | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65221 | Alglucosidase Alfa | One source FDA |
| DrugBank | DB01272 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.